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The present study was undertaken to determine a possible influence of fludarabine (fludarabine phosphate,  
F-ara-AMP) on the cell viability and count. The experiments were performed in vitro on human acute lymphoblastic 
MOLT-4 cells, human acute myeloblastic ML-1 cells, and human histiocytic lymphoma U-937 cells. The research 
was conducted using the spectrophotometric and Beckman Coulter methods. The cell viability was analyzed using 
MTT assay. The cell count was detected using an electronic Z2 Coulter counter. Temporary changes in the cell via-
bility and count were assessed at 24h and 48h after F-ara-AMP application. The in vitro activity of fludarabine pho-
sphate against MOLT-4, ML-1, and U-937 cells was compared. F-ara-AMP applied at the four concentrations - 250 
nM, 500 nM, 750 nM, and 1 µM - distinctly decreased the viability and count of the pathological hematopoietic cells. 
The effects of F-ara-AMP on MOLT-4, ML-1, and U-937 cells were dependent on the tested agent and its dose, the 
time intervals after the agent application, and the cell line used. ML-1 and U-937 cells appeared to be more resistant 
than MOLT-4 cells to the action of fludarabine phosphate. The in vitro response of the three human pathological 
hematopoietic cell lines to the F-ara-AMP action, was shown.
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INTRODUCTION
Fludarabine is an adenine nucleotide analog. Flu-
darabine, marketed as fludarabine phosphate (F-
ara-AMP) under the trade name Fludara, is a che-
motherapy agent (hood and FinLey, 1991; pLunkett 
and SaunderS, 1991; keating et al., 1994; MontiLLo 
et al., 2006, ewaLd et al. 2008). Fludarabine pho-
sphate has been extensively used to successfully 
treat various hematological malignancies (roSS 
et al., 1993; keating et al., 1994; MontiLLo et al., 
2006). Nevertheless, some aspects of the action of 
fludarabine are as yet unclear. Available informa-
tion on biological properties of fludarabine and 
its activity against different pathological hemato- 
poietic cells, is still scarce.
Cell viability and count are the important para-
meters characterizing anticancer activity of chemo-
therapeutic drugs (kaSperS et al., 1995; BorowiCz et 
al., 2012). The MTT assay and Beckman Coulter 
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method are accepted to be the sensitive, simple and 
rapid methods which make it possible to determine 
and compare in vitro viability and mortality in cultu-
red cell lines, and cell sensitivity to various agents.
The purpose of the present study was to eva-
luate the in vitro cell response of the three human 
pathological hematopoietic cell lines to the action 
of fludarabine phosphate. Temporary changes in 
the viability and count of human acute lympho-
blastic cells, human acute myeloblastic cells, and 
human histiocytic lymphoma cells subjected to 
the action of F-ara-AMP were compared using the 
MTT assay and Beckman Coulter method.
MATERIALS AND METHODS
Cells
Human acute lymphoblastic MOLT-4 cells, human 
acute myeloblastic ML-1 cells (ECACC, European 
Collection of Cell Cultures, UK), and human histio-
cytic lymphoma U937 cells (American Type Culture 
Collection, Rockville, MD, USA), were maintained in 
RPMI 1640 medium (Gibco BRL Life Technologies) 
supplemented with 10% fetal calf serum (Gibco 
BRL Life Technologies), 2 mM L-glutamine (Sigma 
Aldrich), and antibiotic antimycotic solution (AAS, 
Sigma Aldrich). AAS contained 20 units of penicil-
lin, 20 µg streptomycin and 0.05 µg amphotericin 
B. The cells were passaged every third day. These 
cells grew expotentially at 37°C in the atmosphere 
of 5% CO2 in air (HERAcell incubator, KendroLab). 
Agent doses and treatment
After a dilution of the cell suspension to a densi-
ty of 15x104 cells/ml, MOLT-4, ML-1, and U937 
cells were exposed to the action of fludarabine 
phosphate (F-ara-AMP, Fludara, Schering), which 
was applied at the four concentrations - 250 nM, 
500nM, 750 nM, and 1 µM. The control material 
consisted of untreated cells. 
Analysis of cell response to F-ara-AMP 
Temporary alterations occurring in the cells were 
analyzed at 24h and 48h after the fludarabine 
phosphate application. At these two time inter-
vals, the viability and count of U-937, ML-1, and 
MOLT-4 cells, were assessed. The cell viability was 
analyzed using MTT assay, and the cell count was 
detected using an electronic Beckman Coulter 
method (Mazur et al., 2012).
Spectrophotometric MTT assay 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl te-
trazolium bromide, Sigma-Aldrich) was dissolved 
in RPMI 1640 medium, at a concentration of 5 mg/
ml, and filtered through a 0,2 µm filter. 100 µl of 
the yellow MTT solution was added to each well of 
24-well plate, containing 1 ml of the cell suspen-
sion, and the cells were incubated at 37°C with 5% 
CO2. Blank solution was prepared according to the 
above procedure using complete medium without 
cells. After the three-hour incubation period, re-
sulting formazan crystals were dissolved with 1 ml 
of acidified isopropanol (0.05 N HCl in absolute 
isopropanol). Absorbance of the obtained solution 
was measured at a wavelength of 570 nm using 
a Pharmacia Ultrospec III spectrophotometer 
(Pharmacia). The extent of MTT conversion to for-
mazan in the cells reflects their viability. The va-
lue of the formazan formed was also expressed as 
a percentage value of the control. 
Electronic cell counting
Samples of the cell suspension were taken from 
 flasks and immediately diluted in ISOTON II (Beck-
man Coulter filtered electrolyte solution based on 
0.9 % saline). 500 μl of the cell suspension was ad-
ded to 4.5 ml of ISOTON II. After the dilution of 
the cell suspension, individual cells were measu-
red using a Z2 Coulter counter (Beckman Coulter, 
USA). The cell count was detected using the counter 
equipped with a 100 μm diameter orifice. The in-
strument was calibrated using 10 μm diameter la-
tex beads (Beckman Coulter CC size standard). The 
flow rate was 500 μl / 12.5 sec. The cell count was 
determined using Z2 AccuComp software (Beckman 
Coulter, USA) and calculated per 1 ml of medium. 
Statistical evaluation
Statistical significance of differences in the amount 
of formazan formed, and in the cell count, were 
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evaluated by an analysis of variance and the Dun-
can’s new multiple range test. A difference with 
P < 0.05 was considered statistically significant. 
The results were confirmed by three independent 
experiments carried out in triplicate.
RESULTS
The influence of fludarabine phosphate on 
MOLT-4, ML-1, and U-937 cells was evalua-
ted. The various patterns of temporary chan-
ges in the optical density of formazan solution 
which reflects the cell viability (Table 1, 2, and 
3, Fig.1) and in the human pathological hema-
topoietic cell count (Table 4, 5, and 6), were ob-
served at 24h and 48h after F-ara-AMP appli- 
cation. 
Experimental 
group
Time intervals  
after cell exposure to F-ara-AMP
24h  48h
No. Drug dose
Optical density of formazan solution 
(x10-2)
 Mean ± SD Mean ± SD
I Control 2,3,4,5,48h5.52 ± 0.17
2,3,4,5,24h
13.50 ± 0.15
II 250 nM 1,4,5,48h4.51 ± 0.71
1,3,4,5,24h
12.45 ± 0.28
III 500 nM 1,54.27 ± 0.50
1,2,4,5
 3.97 ± 0.58
IV 750 nM 1,2,5,48h4.02 ± 0.40
1,2,3,5,24h
1.97 ± 0.42
V 1 µM 1,2,3,4,48h3.35 ± 0.18
1,2,3,4,24h
1.23 ± 0.08
TABLE 1. The optical density of formazan solution determi-
ned in MOLT-4 cells after their exposure to the action of flu-
darabine phosphate
The values are presented as the mean ± standard deviation. A dif-
ference with P < 0.05 was considered statistically significant using 
analysis of variance and Duncan’s new multiple range test. Differen-
ces between experimental groups were indicated as different from 
Group I - 1; Group II - 2; Group III - 3; Group IV - 4; Group V - 5; 
Differences within each experimental group between the two time 
points were given as different from 24h - 24h; 48h - 48h.
TABLE 2.  The optical density of formazan solution determi-
ned in ML-1 cells after their exposure to the action of fluda-
rabine phosphate
Experimental 
group
Time intervals  
after cell exposure to F-ara-AMP
24h 48h
No. Drug dose
Optical density of formazan     solu-
tion (x10-2)
  Mean ± SD  Mean ± SD
I Control 2,3,4,5,48h17.73 ± 0.27
2,3,4,5,24h
38.03 ± 0.87
II 250 nM 1,3,4,5,48h16.90 ± 0.35
1,3,4,5,24h
36.43 ± 0.84
III 500 nM 1,2,4,5,48h14.47 ± 0.68
1,2,4,5,24h
30.33 ± 1.20
IV 750 nM 1,2,3,48h12.99 ± 0.36
1,2,3,5,24h
24.70 ± 0.63
V 1 µM 1,2,3,48h12.82 ± 0.27
1,2,3,4,24h
21.78 ± 0.83
For explanation see Table 1.
TABLE 3. The optical density of formazan solution determi-
ned in U-937 cells after their exposure to the action of fluda-
rabine phosphate
Experimental 
group
Time intervals  
after cell exposure to F-ara-AMP
24h 48h
No. Drug dose
Optical density of formazan solution 
(x10-2)
  Mean ± SD  Mean ± SD
I Control 2,3,4,5,48h19.01 ± 0.30
3,4,5,24h
46.12 ± 1.05
II 250 nM 1,3,4,5,48h18.24 ± 0.61
3,4,5,24h
45.94 ± 0.85
III 500 nM 1,2,4,5,48h16.12 ± 0.40
1,2,4,5,24h
36.70 ± 0.36
IV 750 nM 1,2,3,5,48h14.34 ± 0.36
1,2,3,5,24h
29.74 ± 0.29
V 1 µM 1,2,3,4,48h13.27 ± 0.29
1,2,3,4,24h
25.60 ± 0.60
For explanation see Table 1.
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and 3, respectively. The viability rate of the hu-
man pathological hematopoietic cells is shown in 
Fig.1.
In comparison with the controls, the optical 
density of formazan solution decreased in the re-
maining experimental groups of MOLT-4 cells (Ta-
ble 1), ML-1 cells (Table 2), and U-937 cells (Table 
3) treated with fludarabine phosphate, but a si-
gnificant decrease of the amount of formazan for-
med in U-937 cells was not observed at 48h after 
the application of this adenine nucleotide analog 
(Table 3). Following the exposure of the pathologi-
cal hematopoietic cells to the action of F-ara-AMP, 
the optical density of formazan solution (Table 1, 
2, 3) and the viability rate (Fig. 1) appeared to be 
reduced in a dose- and time dependent manner.
Cell count
The counts of MOLT-4, ML-1 and U-937 cells 
 treated with F-ara-AMP are given in Table 4, 5 and 
6, respectively. 
In relation to the controls, the cell count de- 
creased in all the remaining experimental groups 
of the human pathological hematopoietic cells, 
at two time intervals 24h and 48h after the ap-
plication of fludarabine phosphate. The count of 
MOLT-4 cells (Table 4), ML-1 cells (Table 5), and 
U-937 cells (Table 6) treated with F-ara-AMP, de-
creased in a dose- and time dependent manner. 
DISCUSSION
The effects of fludarabine phosphate on human 
acute lymphoblastic MOLT-4 cells, human acute 
myeloblastic ML-1 cells, and human histiocytic 
lymphoma U937 cells, were compared. It has been 
demonstrated that F-ara-AMP applied at the four 
concentrations - 250 nM, 500 nM, 750 nM and 
1μM, distinctly affected the viability and count of 
MOLT-4, ML-1, and U-937 cells. The influence of 
fludarabine phosphate on the human pathological 
hematopoietic cells was dependent on the tested 
agent and its dose, the time intervals after the 
agent application, and the cell line used. MOLT-4 
cells appeared to be more sensitive than ML-1 and 
U-937 cells to the action of F-ara-AMP. The diffe-
rent effects of fludarabine phosphate on the three 
human pathological hematopoietic cell lines are 
Fig. 1. Effects of fludarabine phosphate on the viability rate 
of MOLT-4 cells (A), ML-1 cells (B) and U-937 cells (C). 
The values are presented as the mean ± standard deviation. 
A difference with P < 0.05 was considered statistically signi-
ficant using analysis of variance and Duncan’s new multiple 
range test. Values not significantly different at P<0.05 : *, **, 
*** - between the particular groups of cells treated with fluda-
rabine phosphate at different doses.
Cell viability
The optical density of formazan solution determi-
ned in MOLT-4, ML-1, and U-937 cells exposed 
to the action of F-ara-AMP is given in Table 1, 2, 
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surely dependent on its metabolism, pharmaco-
kinetic properties, and the cell status (pLunkett et 
al., 1990, 1993; gandhi and pLunkett, 2002). 
Fludarabine phosphate is a water-solu-
ble prodrug that is rapidly converted to the 
free nucleoside 9-β-D-arabinosyl-2-fluoroadenine 
(F-ara-A). F-ara-A is transported into the cell 
and it is then rephosphorylated via deoxycyti-
dine kinase to the 5’-triphosphate derivative, 
F-ara-ATP. This principal active form of flu-
darabine has multiple mechanisms of action, 
which are mostly directed toward DNA. F-ara-
ATP competitively inhibits DNA synthesis via 
inhibition of DNA polymerase, ribonucleoti-
de reductase, DNA primase, and DNA ligase. 
F-ara-ATP prevents elongation of DNA strands 
through direct incorporation into DNA as a false 
nucleotide. Partial inhibition of RNA polymerase II 
and resultant reduction in protein synthesis may 
also occur. It is assumed that effects of F-ara-ATP 
on DNA, RNA and protein synthesis all contribu-
te to inhibition of DNA synthesis and cell growth. 
The cytotoxic effects of fludarabine occur prima-
rily in the S-phase of cell division but this adeni-
ne nucleotide analog is also active against non-
proliferating cells. Nevertheless, the mechanisms 
Experimental 
group
Time intervals  
after cell exposure to F-ara-AMP
24h  48h
No. Drug dose
Cell count (x103)             
  Mean ± SD   Mean ± SD
I Control 2,3,4,5,48h300.82 ± 6.16 
2,3,4,5,24h
567.91 ± 5.71
II 250 nM 1,3,4,5,48h250.90 ± 5.58
1,3,4,5,24h
388.30 ± 27.11
III 500 nM 1,2,4,5,48h233.30 ± 2.90
1,2,4,5,24h
 279.13 ± 4.67
IV 750 nM 1,2,3,5,48h215.16 ± 2.74
1,2,3,5,24h
257.52 ± 2.89
V 1 µM 1,2,3,4,48h204.76 ± 4.12
1,2,3,4,24h
242.55 ± 4.31
For explanation see Table 1.
TABLE 4. The count of MOLT-4 cells after their exposure to 
the action of fludarabine phosphate
TABLE 5. The count of ML-1 cells after their exposure to the 
action of fludarabine phosphate
Experimental 
group
Time intervals  
after cell exposure to F-ara-AMP
24h 48h
No. Drug dose
Cell count (x103)
Mean ± SD   Mean ± SD
I Control 2,3,4,5,48h284.61 ± 12.69
2,3,4,5,24h
688.58 ± 18.28
II 250 nM 1,3,4,5,48h251.67 ± 7.29
1,3,4,5,24h
551.94 ± 19.82
III 500 nM 1,2,5,48h222.32 ± 6.86
1,2,4,5,24h
424.20 ± 6.21
IV 750 nM 1,2,48h211.22 ± 9.77
1,2,3,5,24h
357.14 ± 24.00
V 1 µM 1,2,3,48h208.10 ± 2.62
1,2,3,4,24h
293.51 ± 19.79
For explanation see Table 1.
TABLE 6. The count of U-937 cells after their exposure to the 
action of fludarabine phosphate
Experimental 
group
Time intervals  
after cell exposure to F-ara-AMP
24h 48h
No. Drug dose
Cell count (x103)
  Mean ± SD   Mean ± SD
I Control 2,3,4,5,48h281.35 ± 13.30
2,3,4,5,24h
684.73 ± 21.79
II 250 nM 1,4,5,48h227.65 ± 5.73
1,3,4,5,24h
508.33 ± 46.18
III 500 nM 1,4,5,48h220.13 ± 4.09
1,2,4,5,24h
384.35 ± 18.11
IV 750 nM 1,2,3,5,48h200.20 ± 8.55
1,2,3,5,24h
325.66 ± 13.28
V 1 µM 1,2,3,4,48h174.22 ± 6.79
1,2,3,4,24h
267.12 ± 15.04
For explanation see Table 1.
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of action of F-ara-ATP have not been completely 
characterized (gandhi and pLunkett, 2002; pLunkett 
et al., 1990, 1993, 2003; ewaLd et al., 2008).
To summarize, differences in the potential of 
fludarabine phosphate to cause temporary al-
terations in the viability and count of MOLT-4, 
ML-1, and U-937 cells have been found. The in 
vitro response of the three lines of pathological 
hematopoietic cells to the action of F-ara-AMP is 
shown. In conclusion, the elucidation of biological 
properties of fludarabine and its activity against 
different human pathological hematopoietic 
 cells can considerably improve its clinical appli- 
cation.
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